IL-17抑制剂与炎症性肠病:Vigibase上市后研究
该研究基于全球药物警戒数据库Vigibase,分析IL-17抑制剂治疗患者中胃肠不良事件的报告特征与预后。共识别1129例胃肠个例安全报告,其中850例为炎症性肠病(IBD),279例为结肠炎,主要与司库奇尤单抗(83.6%)和依奇珠单抗(16.3%)相关。多数IBD和结肠炎在治疗开始6个月内被检出,约三分之二患者完全或持续恢复,但部分无恢复或留有后遗症,IBD组死亡4例(1.2%),结肠炎组死亡2例(2.1%)。
要点
- IL-17抑制剂与IBD及结肠炎的新发或加重相关,以司库奇尤单抗报告最多。
- 多数胃肠事件在治疗开始6个月内出现,用药初期应重点监测。
- 用药前应仔细评估胃肠症状并监测肠道炎症生物标志物。
核心结论
- IL-17抑制剂治疗与相当数量的IBD和结肠炎新发或加重相关。
研究设计与样本
- 基于全球药物警戒数据库Vigibase的上市后研究,共识别1129例胃肠个例安全报告。
主要发现
- 1129例胃肠个例安全报告中,IBD 850例(克罗恩病42.5%、溃疡性结肠炎31.9%、未分化IBD 25.6%),结肠炎279例(未分化结肠炎79.2%、显微镜结肠炎10.4%)。
- 报告主要与司库奇尤单抗(83.6%)或依奇珠单抗(16.3%)相关,布罗达鲁单抗仅1例结肠炎(0.1%)。
- 多数IBD和结肠炎在治疗开始6个月内检出:司库奇尤单抗组分别为68.8%和73.5%,依奇珠单抗组分别为100%和66.7%。
- 428例(37.9%)报告了患者结局:IBD和结肠炎患者中分别有59.5%和64.2%完全或持续恢复,33.9%和29.5%无恢复,5.4%和4.2%留有后遗症。
- IBD组死亡4例(1.2%,司库奇尤单抗3例、依奇珠单抗1例),结肠炎组死亡2例(2.1%,均为司库奇尤单抗)。
临床怎么用
- 处方IL-17抑制剂前应仔细评估胃肠症状,并监测肠道炎症生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several gastrointestinal symptoms and chronic inflammatory bowel diseases (IBDs) have been reported after therapy with IL-17 inhibitors. To date, however, no study has shown a clear association between these drugs and IBD onset. We searched on Vigibase, the worldwide pharmacovigilance database, to investigate reporting prevalence, characteristics, and prognosis of all gastroenterological adverse events in patients treated with IL-17 inhibitors. In total, 1,129 gastrointestinal Individual Case Safety Reports (ICSRs) were identified, including 850 IBD (42.5% Crohn's disease, 31.9% ulcerative colitis, and 25.6% undifferentiated IBD) and 279 colitis (mainly undifferentiated colitis (79.2%), and microscopic colitis (10.4%)). ICSRs were associated with secukinumab (SEC, 83.6%) or ixekizumab (IXE, 16.3%), whereas only one colitis occurred with brodalumab (0.1%). Most IBD and colitis cases were detected within 6 months from therapy start in both the SEC (68.8% and 73.5%) and IXE groups (100% and 66.7%). Patients' outcomes were reported in 428 ICSRs (37.9%). Complete or ongoing recovery from symptoms was detected in about two-thirds of patients experiencing IBD (59.5%) or colitis (64.2%), whereas in the other cases, there was no recovery (33.9% and 29.5%) or there were sequelae (5.4% and 4.2%). Fatal events occurred in four patients (1.2%) in the IBD group (3 after SEC and on1e with IXE) and two SEC-treated subjects in the colitis group (2.1%). Treatment with IL-17 inhibitors is associated with a relevant number of exacerbations and new onset of IBD and colitis. Careful evaluation of gastrointestinal symptoms and the monitoring of intestinal inflammatory biomarkers should be recommended before prescribing these drugs.
引用
- Petitpain N, D'Amico F, Yelehe-Okouma M, et al. IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. Clin Pharmacol Ther. 2021. PMID: 33411953. doi:10.1002/cpt.2155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。